A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma

ConclusionFor glioblastoma patients, extending post-radiation temozolomide from 6 to 12  months is well tolerated but does not improve 6mPFS. We could not identify any subset that benefitted from extended treatment. Six months should remain standard-of-care.
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research